PD-1/PD-L1免疫抑制剂在非小细胞肺癌免疫治疗中的研究进展  

Research Progress on Application of PD-1/PD-L1 Immune Checkpoint Blocker Tumor Immunotherapy to Inhibit Signaling Pathways in Non-small Cell Lung Cancer

作　　者：吴柳盛 刘继先[1] 乌达[1] 栾昕宇 罗瑞星 侯清华 刘林壮 吴定旺 徐鹏程[1] 李小强 WU Liu-sheng;LIU Ji-xian;WU Da;LUAN Xin-yu;LUO Rui-xing;Hou Qing-hua;LIU Lin-zhuang;WU Ding-wang;XU Peng-cheng;LI Xiao-qiang(Peking University Sheruhen Hospital,Clinical College of Anhui Medictd University,Shenzhen 518036,China;Department of Gnuluule School,Anhui Medical University,Hefei 230032,China)

机构地区：[1]安徽医科大学北大深圳医院临床学院,北京大学深圳医院,广东深圳518036 [2]安徽医科大学研究生学院,安徽合肥230032

出　　处：《肿瘤学杂志》2021年第9期710-715,共6页Journal of Chinese Oncology

基　　金：广东省自然科学基金面上项目(2018A030313762);深圳市科技计划资助项目(JCYJ20180228162607111)。

摘　　要：近年来免疫检查点领域研究进展迅速,众多新药相继出现,其中包括程序性细胞死亡蛋白1(programmed cell deathprotein1,PD-1)单抗Pembrolizumab和Nivolumab,程序性细胞死亡蛋白配体1(programmedcelldeath protein ligand 1,PD-L1)单抗Atezolizumab。免疫检查点PD-1/PDL1抑制剂给EGFR突变阳性非小细胞肺癌患者带来更多的生存获益,正逐渐改变国内外EGFR突变阳性晚期非小细胞肺癌的治疗模式。全文对PD-1/PD-L1为靶向的肿瘤免疫治疗在晚期EGFR突变阳性非小细胞肺癌患者治疗中的研究进展进行综述。In recent years,research in the field of immune checkpoints has progressed rapidly and many new drugs have emerged,including PD-1 monoclonal antibodies:Pembrolizumab and Nivolumab,PD-L1 monoclonal antibody Atezolizumab.Immune checkpoint PD-1/PD-L1 injection brings survival and remission time to chemotherapy time for EGFR mutation-positive non-small cell lung cancer patients,and it is gradually changing the EGFR mutation-positive advanced non-small cell lung cancer(NSCLC)treatment mode.Here is an overview of the progress in the treatment of non-small cell lung cancer using tumor immunotherapy implanted with the immune checkpoint PD-1/PD-L1 that inhibits the signaling pathway.

关 键 词：PD-1/PD-L1 免疫检查点抑制剂 肿瘤免疫治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]